A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer. - Filho OM; Giobbie-Hurder A; Lin NU; Faggen M; Come S; Openshaw T; Constantine M; Walsh J; Freedman RA; Schneider B; Burstein HJ; Mayer EL (Breast cancer research and treatment, 2021)